Gallbladder removal operations saw a significant 15% annual increase last year, according to newly highlighted data, prompting leading surgeons to call for urgent research into a possible connection with the growing popularity of weight-loss jabs.
These medications, known as GLP-1 receptor agonists, work by mimicking a natural hormone that helps regulate blood sugar and appetite, leading to feelings of fullness and often significant weight reduction. While effective for weight management, particularly for those with obesity and related conditions, they are also associated with various side effects, including nausea, diarrhoea, and in some cases, the formation of gallstones.
Gallstones are hardened deposits of digestive fluid that can form in the gallbladder, causing pain, inflammation, and blockages. Cholecystectomy, the surgical removal of the gallbladder, is a common procedure for symptomatic gallstones, as outlined in NHS guidelines and NICE recommendations for managing gallstone disease. It is well-established that rapid weight loss itself, regardless of the method, is a significant risk factor for developing gallstones due to changes in bile composition.
However, the surgical community is now keen to investigate if the medications themselves contribute to gallstone formation or other gallbladder issues, beyond the effects of rapid weight loss alone. They stress the importance of understanding the full spectrum of potential complications as these drugs become more widely prescribed on the NHS and through private channels to tackle rising obesity rates.
The call for more research aims to provide a clearer picture for patients and healthcare professionals, ensuring that the benefits and risks of these increasingly popular treatments are fully understood and communicated. Individuals considering or currently using weight-loss medications should discuss any concerns with their GP, as this article does not constitute medical advice.